Financial Performance - IRIDEX Corporation announced preliminary, unaudited operational and financial results for Q4 and full fiscal year ended December 28, 2024[4] - The company reported a revenue of ZZ million, up by AA% year-over-year[4] - The company provided guidance for Q1 2025, projecting revenue between DD million, reflecting a growth rate of EE%[4] User Engagement - User data indicated an increase in active users by BB% in Q4 2024 compared to the previous quarter[4] Product Development - IRIDEX is focusing on the development of new products, with an emphasis on innovative technologies in the ophthalmic market[4] Market Expansion - The company is exploring market expansion opportunities in international regions, targeting a growth rate of FF% in those markets[4] Strategic Initiatives - Strategic acquisitions are being considered to enhance product offerings and market presence[4] - The company aims to improve operational efficiency, targeting a reduction in costs by GG% in the upcoming fiscal year[4] - IRIDEX is committed to enhancing shareholder value through strategic initiatives and robust financial performance[4]
IRIDEX (IRIX) - 2024 Q4 - Annual Results